

## InvitroCue announces appointments to management team

### Highlights

- Dr Sunny Tan appointed Senior VP, Scientific Affairs and Corporate Development
- Dr Ramanuj DasGupta appointed Chief Scientific Officer (Non-Executive), Onco-PDO

**Sept 28, 2017** – InvitroCue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce two senior appointments to its management team.

**Dr Sunny Tan** will commence immediately as Senior VP, Scientific Affairs and Corporate Development, leading the company's engagement with scientific and commercial partners. Dr Tan is a well-regarded life sciences and health innovation professional, with broad experience commercialising new technologies to effect better healthcare. Dr Tan's experience includes the commercialisation of biomedical technologies as Vice President of Exploit Technologies, the commercialisation company for Singapore's Agency for Science, Technology and Research (A\*STAR), and investment into early stage biomedical companies at Singapore government investment holding company Temasek Holdings. Dr Tan holds a PhD in Biochemistry and Molecular Biology (Australian National University), and a BSc in Biotechnology with First Class Honours (University of New South Wales).

Serving as Scientific Adviser to InvitroCue since 2016, **Dr Ramanuj DasGupta** will expand his role as a Non-Executive Chief Scientific Officer overseeing the development of the service pipeline for InvitroCue's Onco-PDO business. Dr DasGupta trained as a development and cancer biologist, and is a co-founder of the Onco-PDO technology, which is used to grow micro-tumour models outside a patient's body and test those models against a range of drug candidates to determine targeted treatment options. Dr DasGupta is currently a Senior Investigator/Group Leader in Cancer Therapeutics and Stratified Oncology at the Genome Institute of Singapore/A\*STAR, and an Associate Professor at the New York University School of Medicine focusing the work of his lab on novel screening platforms and Precision Oncology. Dr DasGupta holds a PhD in Developmental Biology (University of Chicago), BA in Genetics (Cambridge) and BSc in Chemistry (Delhi University).

These two appointments provide InvitroCue with deep commercial capabilities and further scientific leadership at an important time in the company's development.

Commenting on the appointments, InvitroCue Executive Director, Dr Steven Fang said, "We are delighted by the appointments of Dr Tan and Dr DasGupta to our management team, both of whom bring world class corporate development and scientific expertise into our company as we expand our footprint globally, and drive further adoption of our unique approach to better treatment of cancer."

- ENDS -

**For more information, please contact:**

Martin D. Bach, VP Operations

T: +65 6460 0490

[martind.bach @invitrocue.com](mailto:martind.bach@invitrocue.com)

**About Invitrocue**

Invitrocue is a leading healthcare bio-analytic solutions including *in vitro* cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for use in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine). Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A\*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.